<DOC>
	<DOCNO>NCT01976858</DOCNO>
	<brief_summary>Polyethylene Glycol Loxenatide ( PEX168 ) new human glucagon-like peptide 1 ( GLP-1 ) analogue create basis Exenatide modify polyethylene glycol ( PEG ) . This study aim evaluate PK , PD safety 8-week continuous treatment PEX168 .</brief_summary>
	<brief_title>A Phase I Study 8-week Continuous Treatment With Polyethylene Glycol Loxenatide Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1. aged 2065 year old , male female , diagnosis type 2 diabetes accord 1999 WHO criteria 3 month . 2 . HbA1C 7.010.0 % fast plasma glucose 7.010.0 mmol/L treatment diet , exercise single oral hypoglycemic agent ( metformin , glimepiride pioglitazone ) . 3. unused insulin within 3 month prior enrollment . 4 . Body mass index within range 19 35 , body weight change exceed 10 % past 3 month . 5 . Normol liver , kidney , heart function . 6 . Willing use physical mean contraception trial stage . 7. voluntarily participate study . 1 . 1 diabetes . 2. used GLP1 , GLP1 analogs DPP4 inhibitor past 3 month . 3. diabetic ketoacidosis , diabetic hyperosmolar nonketotic coma patient history 4 . There history severe hypoglycemia : low blood sugar cause drowsiness , unconsciousness , nonsense , even coma . 5. severe diabetes complication ( renal , retinal , nerve , vascular disease ) . 6. acute chronic pancreatitis history ; 7. heart failure , unstable angina , severe arrhythmia , patient history myocardial infarction ; 8 . There history hypertension blood pressure well control : SBP &gt; 160mmHg / DBP &gt; 95mmHg person ; 9. severe chronic gastrointestinal disease ( active ulcer nearly six month ) affect drug absorption patient treat ; 10 . There obvious blood system diseases ; 11 . There endocrine system disease , hyperthyroidism , etc . ; 12. severe trauma surgery , severe infection ; 13. mental illness , drug substance abuse alcoholism ( drink least 2 time per week , 100g drink ) ; 14. use drug may affect study , within 3 month treatment subject participate clinical trial ; 15. within past six month 400ml blood loss ( include blood , trauma reason ) ; 16. receive steroid receive cancer treatment ; 17. prepared pregnancy pregnancy test female patient ; 18. hepatitis B HBeAg , hepatitis C antibody positive , HIV antibody positive , syphilis antibody positive . 19. skin test positive PEX168 ; 20 . The researcher consider factor subject participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>PEX168 , diabetes , phase I</keyword>
</DOC>